ProQR Therapeutics (NASDAQ:PRQR) reported quarterly losses of $(0.15) per share which met the analyst consensus estimate. This is a 50 percent decrease over losses of $(0.10) per share from the same period last year. The company reported quarterly sales of $2.381 million which missed the analyst consensus estimate of $5.530 million by 56.94 percent. This is a 49.90 percent decrease over sales of $4.752 million the same period last year.